A Phase 1 Study of KHN702 Tablets in Healthy Subjects

Launched by CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD. · Jun 23, 2025

Keywords

ClinConnect Summary

This clinical trial is a first-step study to test a new medicine called KHN702 in healthy adult volunteers. The main goal is to see if KHN702 tablets are safe and well-tolerated when given in different doses, either as a single dose or multiple doses over time. This study will be carefully controlled, meaning some participants may receive the medicine while others receive a placebo (a pill without the medicine), and neither the participants nor the researchers will know who gets which until the study is over.

To take part, volunteers need to be between 18 and 45 years old, weigh at least 50 kg for men or 45 kg for women, and have a healthy body weight range. Participants must also agree to use effective birth control during the study and for a few months afterward. People with significant health problems, recent surgeries, allergies to certain medicines, or those who smoke heavily or drink a lot of alcohol won’t be eligible. During the study, participants will undergo regular health checks and follow specific rules, like avoiding certain foods, drinks, and activities that could affect how the medicine works. This is an important early trial to ensure KHN702 is safe before testing it in patients with illnesses.

Gender

ALL

Eligibility criteria

• inclusion criteria:
• • 1.Age: 18 to 45 years old (inclusive), Male or female. 2.Body weight: ≥ 50 kg for male and ≥ 45 kg for female, body mass index: 19\~26 kg/m2 (inclusive).
• • 3. Effective contraception measures and no sperm/egg donation plan from signing the informed consent to 3 months after last dose.
• • 4.Fully understand the procedures and sigh the informed consent. exclusion criteria：
• • 1. Have clinically significant medical history or clinical manifestations, including but not limited to the history of any clinically serious disease such as hematological system, circulatory system,digestive system, urinary system, respiratory system, central nervous system,immunology, endocrine system cardiovascular system, malignant tumors, metabolic abnormalities, or any other disease or physiological condition that may interfere with the results .
• • 2. Subjects with clinically significant abnormalities in vital signs, physical examination, 12 lead electrocardiogram, laboratory examination, abdominal color Doppler ultrasound and chest X-ray during screening period, as determined by the investigator.
• • 3. Dysphagia or history of gastrointestinal diseases, liver and kidney diseases that can affect the pharmacokinetic behavior of drugs as judged by the investigator.
• • 4. Had surgery within 3 months before screening, or planned surgery during the study period, or had surgery that would affect drug absorption, distribution, metabolism, and excretion.
• • 5. Allergic to the IMP or its excipients, or allergic to two or more other drugs, food and environment, or prone to skin rash, urticaria and other allergic symptoms.
• • 6. Allergic to natural light / UV, or phototoxic reaction after previous use of specific drugs (such as fluoroquinolones and tetracyclines).
• • 7. There are risk factors for cardiac disease, including but not limited to congenital long QT syndrome, torsade de pointes or torsade de pointes (such as hypokalemia, hypomagnesemia, family history of long QT syndrome). Currently, class IA \[such as quinidine or procainamide\] or class III \[such as amiodarone or sotalol\] antiarrhythmic drugs or other drugs known to affect QT interval are used. Or QTc interval (QTCF) corrected according to fridericia's criteria \> 450 ms in males and \> 470 ms in females at screening or other 12 lead ECG abnormalities with clinical significance.
• • 8. Alanine aminotransferase (ALT) and / or aspartate aminotransferase (AST) and / or total bilirubin (TBIL), or serum creatinine (CR) exceeded the upper limit of normal at screening.
• • 9. Positive test for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody and treponema pallidum antibody at Screening.
• • 10. Systolic blood pressure ≥ 140 mmHg and / or diastolic blood pressure ≥ 90 mmHg at screening.
• • 11. Vaccinated within 30 days before screening.
• • 12. Any drugs that affects the absorption, metabolism or elimination of the drug has been used within 30 days before administration.
• • 13. Any drugs or health care products (including Chinese herbal medicine and vitamins) used within 14 days before the first administration of the study.
• • 14. Have special requirements for diet and cannot comply with the unified diet.
• • 15. Consumption of foods or juices containing alcohol or caffeine, or having strenuous exercise, or other factors affecting the absorption, distribution, metabolism, excretion of drugs with 48 hours before the first dose. Or disagree to stop drinking tea, coffee and / or caffeinated beverages and foods during the trial.
• • 16. Average daily smoking of more than 5 cigarettes within the 3 months prior to screening or refuse to abstain from smoking during the trial.
• • 17. A history of alcohol abuse or alcohol abuse within 6 months before screening (defined as an average intake of alcohol \> 14 units per week, 1 unit ≈ 285 ml of beer with an alcohol content ≥ 3.5%, or 25 ml of spirits with an alcohol content ≥ 40%, or 85 ml of wines with an alcohol content ≥ 12%), or a positive alcohol test at the screening, or unable to abstain from alcohol during the trial.
• • 18. Donation of blood or significant blood loss ≥ 400 mL in 3 month prior to screening.
• • 19. Substance abuse-related disorder or a history of drug, or positive drug screen at screening and Day -1.
• • 20. Positive pregnancy test, or lactating women.
• • 21. Participate in other clinical trials within 3 months before screening (participation refers to receiving drug administration or device treatment for the trial).
• • 22. Subjects with other factors deemed ineligible to participate in the trial by the Investigator.